RedPath Integrated Pathology is the only commercial laboratory to offer the patented PathFinderTG® testing services for resolving  "indeterminate and equivocal" cancer diagnoses that lead to suboptimal treatment planning.

RedPath is a CLIA certified and CAP accredited commercial laboratory that integrates molecular DNA analysis with the original pathology review. We provide early and definitive cancer diagnostic support for pathologists and clinicians when there is a diagnostic dilemma or standard testing is inconclusive. 

PathFinderTG was developed over a 17 year period, and is clinically validated with up to a 95% accuracy rate as reported in peer reviewed medical journals.  Each PathFinderTG application has its own clinical validation studies and the technology has been reported on directly 129+ times.  To date, more than 15,000 specimens have been analyzed using PathFinderTG.

PathFinderTG is an important advancement in personalized medicine.  DNA-supported diagnoses are highly informative for pre-cancerous and cancerous conditions and with respect to biologic aggressiveness and chemo-responsiveness at the cellular level.

Our turnaround time is normally 5 business days and the PathFinderTG diagnostic tests are easy to order.